Albumin priming enables safe and effective red blood cell exchange in low-weight children with sickle cell disease

Area of Science:

• Pediatric Hematology
• Transfusion Medicine
• Apheresis Technology

Background:

• Red blood cell exchanges (RCE) are vital for managing sickle cell anemia (SCA) complications.
• Low body weight in young children presents a challenge for standard RCE procedures.
• Therapeutic apheresis platforms like Spectra Optia offer solutions for pediatric patients.

Purpose of the Study:

• To evaluate the feasibility, safety, and efficacy of using albumin for priming (RCE/Alb-primed) in RCE procedures for low-weight children with SCA.
• To assess the suitability of albumin priming in pediatric patients under specific weight and hematocrit criteria.
• To determine if RCE/Alb-primed achieves target post-procedure hematocrit and fraction of cells remaining (FCR).

Main Methods:

• Retrospective analysis of 153 RCE/Alb-primed sessions in 19 children (12-23 kg) with SCA.
• Albumin priming was used on the Spectra Optia apheresis system.
• Monitoring for Grade 2 adverse events (AEs) and comparison of post-apheresis hematocrit and FCR to expected values.

Main Results:

• A low incidence of complications was observed, with only one transient Grade 2 AE (decreased blood pressure, increased heart rate, fatigue).
• Achieved target post-apheresis hematocrit and fraction of cells remaining (FCR) values.
• The method was feasible and safe across various indications including emergency, pre-surgical, and routine RCE programs.

Conclusions:

• Albumin priming for RCE is a safe and efficient method for treating young children with SCA, particularly those weighing less than 25 kg.
• This technique effectively overcomes the weight barrier, making RCE more accessible for pediatric SCA patients.
• RCE/Alb-primed should be considered a standard option for both curative and prophylactic RCE programs in pediatric SCA.